BACKGROUND: Clinical heterogeneity in the development of levodopa-induced dyskinesias (LID) suggests endogenous factors play a significant role in determining their overall prevalence. OBJECTIVE: We hypothesised that single nucleotide polymorphisms (SNPs) in specific genes may result in a clinical phenotype conducive to an increased risk of LID. METHODS: We examined the influence of SNPs in the catechol-O-methyltransferase (COMT), monoamine oxidase A (MAO-A) and brain-derived neurotrophic factor (BDNF) genes on LID in a cohort of 285 pathologically confirmed Parkinson's disease patients, using data from their complete disease course. RESULTS: Dyskinetic patients demonstrated younger age at disease onset (60.3 vs. 66.4 years, p < 0.0001), a longer disease duration (17.0 vs. 12.0 years, p < 0.0001) and a higher maximum daily levodopa equivalent dose (LED; 926.7 vs. 617.1 mg/day, p < 0.0001) than patients without dyskinesias. No individual SNP was found to influence prevalence or time to onset of dyskinesias, including after adjustment for known risk factors. We observed that patients carrying alleles conferring both high COMT activity and increased MAO-A mRNA expression received significantly higher maximum and mean daily LEDs than those with low enzyme activity/mRNA expression (max LED: 835 ± 445 vs. 508 ± 316 mg; p = 0.0056, mean LED: 601 ± 335 vs. 398 ± 260 mg; p = 0.025). CONCLUSIONS: Individual SNPs in BDNF, COMT and MAO-A genes did not influence prevalence or time to onset of dyskinesias in this cohort. The possibility that combined COMT and MAO-A genotype is a significant factor in determining an individual's lifetime levodopa exposure warrants further investigation.
BACKGROUND: Clinical heterogeneity in the development of levodopa-induced dyskinesias (LID) suggests endogenous factors play a significant role in determining their overall prevalence. OBJECTIVE: We hypothesised that single nucleotide polymorphisms (SNPs) in specific genes may result in a clinical phenotype conducive to an increased risk of LID. METHODS: We examined the influence of SNPs in the catechol-O-methyltransferase (COMT), monoamine oxidase A (MAO-A) and brain-derived neurotrophic factor (BDNF) genes on LID in a cohort of 285 pathologically confirmed Parkinson's disease patients, using data from their complete disease course. RESULTS: Dyskinetic patients demonstrated younger age at disease onset (60.3 vs. 66.4 years, p < 0.0001), a longer disease duration (17.0 vs. 12.0 years, p < 0.0001) and a higher maximum daily levodopa equivalent dose (LED; 926.7 vs. 617.1 mg/day, p < 0.0001) than patients without dyskinesias. No individual SNP was found to influence prevalence or time to onset of dyskinesias, including after adjustment for known risk factors. We observed that patients carrying alleles conferring both high COMT activity and increased MAO-A mRNA expression received significantly higher maximum and mean daily LEDs than those with low enzyme activity/mRNA expression (max LED: 835 ± 445 vs. 508 ± 316 mg; p = 0.0056, mean LED: 601 ± 335 vs. 398 ± 260 mg; p = 0.025). CONCLUSIONS: Individual SNPs in BDNF, COMT and MAO-A genes did not influence prevalence or time to onset of dyskinesias in this cohort. The possibility that combined COMT and MAO-A genotype is a significant factor in determining an individual's lifetime levodopa exposure warrants further investigation.
Authors: Caroline Williams-Gray; An Goris; Thomas Foltynie; Alastair Compston; Stephen Sawcer; Roger A Barker Journal: J Neurol Date: 2009-02-16 Impact factor: 4.849
Authors: Stanley Fahn; David Oakes; Ira Shoulson; Karl Kieburtz; Alice Rudolph; Anthony Lang; C Warren Olanow; Caroline Tanner; Kenneth Marek Journal: N Engl J Med Date: 2004-12-09 Impact factor: 91.245
Authors: L Parkkinen; S S O'Sullivan; M Kuoppamäki; C Collins; C Kallis; J L Holton; D R Williams; T Revesz; A J Lees Journal: Neurology Date: 2011-09-14 Impact factor: 9.910
Authors: Lonneke M L de Lau; Dagmar Verbaan; Johan Marinus; Peter Heutink; Jacobus J van Hilten Journal: Mov Disord Date: 2011-11-14 Impact factor: 10.338
Authors: T Foltynie; B Cheeran; C H Williams-Gray; M J Edwards; S A Schneider; D Weinberger; J C Rothwell; R A Barker; K P Bhatia Journal: J Neurol Neurosurg Psychiatry Date: 2008-10-31 Impact factor: 10.154
Authors: Giovanni Fabbrini; Jonathan M Brotchie; Francisco Grandas; Masahiro Nomoto; Christopher G Goetz Journal: Mov Disord Date: 2007-07-30 Impact factor: 10.338
Authors: Thomas Foltynie; Simon G J Lewis; Terry E Goldberg; Andrew D Blackwell; Bhaskar S Kolachana; Daniel R Weinberger; Trevor W Robbins; Roger A Barker Journal: J Neurol Date: 2005-03-21 Impact factor: 4.849
Authors: Cynthia D J Kusters; Kimberly C Paul; Ilaria Guella; Jeff M Bronstein; Janet S Sinsheimer; Matt J Farrer; Beate R Ritz Journal: Parkinsonism Relat Disord Date: 2017-11-24 Impact factor: 4.891